Pharmaceutics Practical II Lab Manual Final
Pharmaceutics Practical II Lab Manual Final
Approved
by
Pharmacy Council of India, New Delhi
Affiliated
to
Rajiv Gandhi University of Health Sciences
Karnataka
Bengaluru – 560041
India
LAB MANUAL
PHARMACEUTICS PRACTICAL-II
SL NO LIST OF EXPERIMENTS
1 Preparation & Evaluation of Paracetamol Solid Dispersion by Melting Method
2 Preparation & Evaluation of Paracetamol Solid Dispersion by Solvent
Evaporation Method
3 Comparison of Dissolution Profile of two Different Marketed Products
4 Determination of Percentage Protein Binding of Drugs
5 Bioavailability Studies of Paracetamol in Animals
6 Clinical Data Development Manual
7 Formulation & Evaluation of Cold Creams
8 Formulation & Evaluation of Vanishing Creams
9 Formulation & Evaluation of Toothpaste
10 Formulation & Evaluation of Shampoo
11 Addressing Dry Skin, Acne, Blemish, Wrinkles, Bleeding Gums and Dandruff
Experiment No: 01
Requirements:
PRINCIPLE:
The term solid dispersion refers to a group of solid products consisting of at least two different
components, generally a hydrophilic matrix and a hydrophobic drug. The matrix can be either
crystalline or amorphous. The drug can be dispersed molecularly, in amorphous particles
(clusters) or in crystalline particles.
Methods of Preparation of Solid Dispersions:
1. Melting method
2. Solvent method
3. Melting solvent method (melt evaporation)
4. Melt extrusion method
5. Lyophilisation Technique
6. Melt Agglomeration Process
7. The use of surfactant
8. Electrospinning
9. Super Critical Fluid (SCF) Technology
10. Direct capsule filling
11. Dropping solution method
12. Co-precipitation method
1
Advantages of solid dispersions:
Solid dispersions are not broadly used in commercial products due to mainly the problem of
crystallization of the components from amorphous state during processing (mechanical stress)
or storage (temperature and humidity stress). Moisture may increase drug mobility and promote
drug crystallization and thus may hamper storage stability of amorphous pharmaceuticals.
Phase separation, crystal growth or conversion of a product to more stable structure from
metastable crystalline form during storage are also considered to be major hurdles to
commercialize solid dispersions as they result in decreased solubility and thus dissolution rate
Paracetamol is a potent anti‐inflammatory analgesic agent indicated for acute and chronic
treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylytis. Paracetamol
suffered from low and variable bioavailability which was attributed to its low water solubility.
The increase in dissolution rate of poorly water soluble drugs from SDs can be attributed to
one or combination of different factors Among the popular carriers used in the formulation of
2
SD are polyethylene glycols (PEGs). They are widely used because of their hydrophilicity, low
melting point, and low toxicity.
Solid dispersions were prepared by melting the accurately weighed amounts of carriers (PEG
4000, PEG 6000, Mannitol and Urea) in a water bath and the drug was dispersed in the molten
solution. Solvent Evaporation method was used for the preparation of solid dispersions.
Briefly appropriate amount of paracetamol was taken in china dish and required amount of
carriers (PEG 4000, PEG 6000, Mannitol and Urea) were added to prepare required drug to
carrier ratio for formulations. Then the mixture was heated under controlled temperature to
melt drug and carrier with continuous stirring. The melted preparation was transferred to
porcelain tile to solidify and cooled in an ice bath. The solid dispersions prepared were
pulverized and sifted (80#) and stored in a desiccator.
3
Stock solution 2: 10 ml of this (stock solution 1) is diluted to 100ml with phosphate buffer pH
5.8 to get a stock solution containing 100 µg/ml of drug. The stock solution was filtered through
Whatmann filter paper No.41.
Dilutions: Take the respective samples (0.2ml,0.4ml, 0.6ml, 0.8ml, 1ml, 1.2ml) in each test
tube, add phosphate buffer 5.8 to make total volume of 10 ml to produce (2, 4, 6, 8, 10, 12
µg/ml) respectively.
The dilution was analysed in UV-Visible spectrophotometer and the absorbance were recorded.
The standard plot was constructed and the standard equation was derived.
Accurately weighed amount of sample was taken for dissolution studies. Aliquots of sample
were withdrawn at predetermined intervals of time and analysed for drug release by measuring
the absorbance at 243nm using phosphate buffer pH 5.8 as dissolution medium. The volume
withdrawn at each time intervals were replaced with same quantity of fresh medium.
4
2. Drug Content Analysis:
Formulation
Concentration Absorbance (nm) Assay Value (µg/ml)
Code
SD1
SD2
SD3
SD4
SD5
SD6
10 µg/ml
SD7
SD8
SD9
SD10
SD11
SD12
3. In vitro release studies:
Conc. Conc. Conc.
Time Absorbance CDR CDR
Sl. No In In µg/ In µg/ %CDR
(Mins) (nm) in µg in mg
µg/ml 5 ml 900 ml
Report: Paracetamol Solid Dispersions were prepared by Melting method. The Evaluation of
the same was performed.
5
Experiment No: 02
AIM: To prepare & evaluate Paracetamol Solid Dispersion by Solvent Evaporation Method
Requirements:
PRINCIPLE:
The term solid dispersion refers to a group of solid products consisting of at least two different
components, generally a hydrophilic matrix and a hydrophobic drug. The matrix can be either
crystalline or amorphous. The drug can be dispersed molecularly, in amorphous particles
(clusters) or in crystalline particles.
Methods of Preparation of Solid Dispersions:
1. Melting method
2. Solvent method
3. Melting solvent method (melt evaporation)
4. Melt extrusion method
5. Lyophilisation Technique
6. Melt Agglomeration Process
7. The use of surfactant
8. Electrospinning
9. Super Critical Fluid (SCF) Technology
10. Direct capsule filling
11. Dropping solution method
12. Co-precipitation method
6
Advantages of solid dispersions:
Solid dispersions are not broadly used in commercial products due to mainly the problem of
crystallization of the components from amorphous state during processing (mechanical stress)
or storage (temperature and humidity stress). Moisture may increase drug mobility and promote
drug crystallization and thus may hamper storage stability of amorphous pharmaceuticals.
Phase separation, crystal growth or conversion of a product to more stable structure from
metastable crystalline form during storage are also considered to be major hurdles to
commercialize solid dispersions as they result in decreased solubility and thus dissolution rate
Paracetamol is a potent anti‐inflammatory analgesic agent indicated for acute and chronic
treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Paracetamol
suffered from low and variable bioavailability which was attributed to its low water solubility.
The increase in dissolution rate of poorly water-soluble drugs from SDs can be attributed to
one or combination of different factors Among the popular carriers used in the formulation of
7
SD are polyethylene glycols (PEGs). They are widely used because of their hydrophilicity, low
melting point, and low toxicity.
Stock solution 2: 10 ml of this (stock solution 1) is diluted to 100ml with phosphate buffer pH
5.8 to get a stock solution containing 100 µg/ml of drug. The stock solution was filtered through
Whatmann filter paper No.41.
Dilutions: Take the respective samples (0.2ml,0.4ml, 0.6ml, 0.8ml, 1ml, 1.2ml) in each test
tube, add phosphate buffer 5.8 to make total volume of 10 ml to produce (2, 4, 6, 8, 10, 12
µg/ml) respectively.
The dilution was analysed in UV-Visible spectrophotometer and the absorbance were recorded.
The standard plot was constructed and the standard equation was derived.
8
Drug content analysis (Assay):
Accurately weighed amount of sample was taken for dissolution studies. Aliquots of sample
were withdrawn at predetermined intervals of time and analysed for drug release by measuring
the absorbance at 243nm using phosphate buffer pH 5.8 as dissolution medium. The volume
withdrawn at each time intervals were replaced with same quantity of fresh medium.
Formulation
Concentration Absorbance (nm) Assay Value (µg/ml)
Code
SD1
SD2
SD3
SD4
SD5
10 µg/ml
SD6
SD7
SD8
SD9
SD10
9
In vitro release studies:
Conc. Conc. Conc.
Time Absorbance CDR CDR
Sl. No In In µg/ In µg/ %CDR
(Mins) (nm) in µg in mg
µg/ml 5 ml 900 ml
Report: Paracetamol Solid Dispersions were prepared by Solvent Evaporation method. The
Evaluation of the same was performed.
10
Experiment No: 03
Requirements:
PRINCIPLE:
Dissolution-
A drug is expected to be released from solid dosage forms (granules, tablets, capsules, etc) and
immediately go into molecular solution. This process is called dissolution.
11
Dissolution test apparatus-
Procedure:
Stock solution 2: 10 ml of this (stock solution 1) is diluted to 100ml with phosphate buffer pH
5.8 to get a stock solution containing 100 µg/ml of drug. The stock solution was filtered through
Whatmann filter paper No.41.
Dilutions: Take the respective samples (0.2ml,0.4ml, 0.6ml, 0.8ml, 1ml, 1.2ml) in each test
tube, add phosphate buffer 5.8 to make total volume of 10 ml to produce (2, 4, 6, 8, 10, 12
µg/ml) respectively.
The dilution was analysed in UV-Visible spectrophotometer and the absorbance were recorded.
The standard plot was constructed and the standard equation was derived.
12
B. In vitro release study of 2 different marketed paracetamol tablet (Product 1, Product 2)-
Two marketed tablets of paracetamol were taken and dissolution study was performed.
Dissolution Studies were conducted in USP Apparatus 2 i.e. Paddle Apparatus (Elecrolab,
Mumbai) with triplicate set for each brand. The dissolution medium was 900 ml of phosphate
buffer pH 5.8. The paddle rotation speed was kept at 50 rpm for 60 minutes. Percentage of drug
dissolved from the tablet was calculated. Aliquots of sample were withdrawn at predetermined
intervals of time and analysed for drug release by measuring the absorbance at 243nm using
phosphate buffer pH 5.8 as dissolution medium. The volume withdrawn at each time intervals
were replaced with same quantity of fresh medium.
13
Table 2: Dissolution Profile of Marketed Product 2:
Conc. Conc. Conc.
Time Absorbance CDR CDR
Sl. No In In µg/ In µg/ %CDR
(Mins) (nm) in µg in mg
µg/ml 5 ml 900 ml
1 5
2 10
3 15
4 30
5 45
6 60
Report:
The % CDR of two different marketed products were found to be:
• Product 1-…………….
• Product 2-…………….
14
Experiment No: 04
AIM: To determine the percentage protein binding of Diclofenac sodium and paracetamol
Requirements:
PRINCIPLE:
A drug in blood exists in two forms: bound and unbound. Depending on a specific drug's
affinity for plasma protein, a proportion of the drug may become bound to plasma proteins,
with the remainder being unbound. If the protein binding is reversible, then a chemical
equilibrium will exist between the bound and unbound states, such that:
Notably, it is the unbound fraction which exhibits pharmacologic effects when the drug
undergoes metabolism in the liver whereas the bounded drug will accumulate and distribute
into the tissues leading to a decrease in plasma concentration profile.
• The Drug:
• The Protein:
15
• Drug Interaction:
For example, drug protein binding may be reduced in uremic patients & in patients with
hepatic disease.
Diclofenac is an NSAID used to treat the signs and symptoms of osteoarthritis and rheumatoid
arthritis. It is almost completely absorbed after oral administration; it is subjected to first-pass
metabolism so that about 50% of the drug reaches the systemic circulation in the unchanged
form. More than 99% is bound to plasma proteins, primarily to albumin.
Human serum albumin is the primary protein present in human blood plasma. The main
function of albumin is to maintain the oncotic pressure of blood. It binds to water, cations (such
as Ca2+, Na+ and K+), fatty acids, hormones, bilirubin, thyroxine (T4) and pharmaceuticals
(including barbiturates). Albumin represents approximately 50% of the total protein content in
healthy humans. Human albumin is a small globular protein (molecular weight: 66.5 kDa),
consisting of a single chain of 585 amino acids organized in three repeated homolog domains
(sites I, II, and III). Each domain comprises two separate sub-domains (A and B).
Procedure:
Stock solution 2: 10 ml of this (stock solution 1) is diluted to 100ml with phosphate buffer pH
6.8 to get a stock solution containing 100 µg/ml of drug. The stock solution was filtered through
Whatmann filter paper No.41.
Dilutions: Take the respective samples (0.2ml,0.4ml, 0.6ml, 0.8ml, 1ml) in each test tube, add
phosphate buffer 6.8 to make total volume of 10 ml to produce (2, 4, 6, 8, 10 µg/ml)
respectively.
16
The dilution was analysed in UV-Visible spectrophotometer (absorption maxima-273 nm) and
the absorbance were recorded. The standard plot was constructed and the standard equation
was derived.
Stock solution 2: 10 ml of this (stock solution 1) is diluted to 100ml with phosphate buffer pH
5.8 to get a stock solution containing 100 µg/ml of drug. The stock solution was filtered through
Whatmann filter paper No.41.
Dilutions: Take the respective samples (0.2ml,0.4ml, 0.6ml, 0.8ml, 1ml, 1.2ml) in each test
tube, add phosphate buffer 5.8 to make total volume of 10 ml to produce (2, 4, 6, 8, 10, 12
µg/ml) respectively.
The dilution was analysed in UV-Visible spectrophotometer (absorption maxima-249 nm) and
the absorbance were recorded. The standard plot was constructed and the standard equation
was derived.
Divide the protein solution into two equal parts containing 50 ml each. Weigh and dissolve 50
mg 50 mg of drug to each of the above half. Study the % drug protein binding by following
technique.
E. Centrifugation technique-
17
will be takes as blank in another centrifuge tube, carry out centrifugation at 2000 rpm for 1 hr.
Collect the supernatant liquid of the protein drug solution & dilute suitably to the Beer range
& measure the absorbance at 273 nm for diclofenac & 249 nm for paracetamol.
F. Dialysis Method-
Drug release by diffusion will be studied using Franz Diffusion cell assembly, fill phosphate
buffer pH 6.8/ 5.8 in the receiver compartment, close the mouth with a cellophane membrane,
which is pretreated by soaking in acidic buffer. Fill 10 ml of the drug protein solution in the
donor compartment at particular time intervals & replace with phosphate buffer pH 7.2. Dilute
suitably & measure the absorbance at 273 nm for diclofenac & 249 nm for paracetamol.
Observation & Calculation:
1) Standard curve of Diclofenac:
Sl. No Concentration (µg/ml) Absorbance (nm)
1 2
2 4
3 6
4 8
5 10
2) Standard curve of Paracetamol:
Sl. No Concentration (µg/ml) Absorbance (nm)
1 2
2 4
3 6
4 8
5 10
6 12
3) In vitro release studies:
18
Table 2: Release Profile of Paracetamol with 4% albumin:
Conc. Conc.
Time Absorbance CDR in CDR in
Sl. No In In µg/ %CDR
(Mins) (nm) µg mg
µg/ml 30 ml
1 5
2 10
3 15
4 30
5 45
6 60
Report:
The % protein bound Diclofenac was found to be …………
The % protein bound Paracetamol was found to be …………
19
Experiment No: 05
DETERMINATION OF BIOAVAILABILITY (BA) IN ANIMAL
MODELS
AIM: To determine the bioavailability (BA) study of paracetamol (PCM) in animal model
(mice).
Requirements:
• Chemical: PCM tablet
• Apparatus: Oral gavage needles syringes, blood collections & blood chemistry
analyzer.
• Model: Mice.
PRINCIPLE:
The bioavailability of Paracetamol (PCM) is typically higher after intravenous administration
than oral administration. This is because the drug is delivered directly into the bloodstream
after the IV administration by passing the First pass metabolism that occurs in the liver after
oral administration. The bioavailability (BA) of PCM can be determined by measuring the
plasma conc. of PCM over time administration of the drug. The area under the plasma conc.
time curve (AUC) is measures of bioavailability of drug:
𝐀𝐔𝐂𝐨𝐫𝐚𝐥
𝐁𝐢𝐨𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 (𝐁𝐀) = 𝐀𝐔𝐂𝐈𝐕
Procedure:
i. To follows the steps as following, take mice where weight was selected & housed in
departmental animal house.
ii. Calculated their doses (PCM) based on their weight.
iii. Administer the PCM tablets to the mice orally using oral gavage needles.
iv. Collect blood samples from the mice at pre-determined time interval after administration
of PCM tablet.
v. Analyze the blood sample for the con. of PCM.
vi. Calculate the bioavailability of PCM by composing the conc. of PCM in the blood after
the oral administration to the con. od the PC in the blood after the intravenous
administration.
20
𝐂𝐨𝐧𝐜.𝐨𝐟 𝐏𝐂𝐌 𝐛𝐥𝐨𝐨𝐝 𝐚𝐟𝐭𝐞𝐫 𝐨𝐫𝐚𝐥 𝐚𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐚𝐫𝐭𝐢𝐨𝐧
𝐁𝐢𝐨𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 = 𝐂𝐨𝐧𝐜.𝐨𝐟 𝐏𝐂𝐌 𝐛𝐥𝐨𝐨𝐝 𝐚𝐟𝐭𝐞𝐫 𝐈𝐧𝐭𝐫𝐚𝐯𝐞𝐧𝐨𝐮𝐬 𝐚𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐚𝐫𝐭𝐢𝐨𝐧 𝐗 𝟏𝟎𝟎
𝟔𝟓𝟎𝐦𝐠
𝐁𝐢𝐨𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 (𝐁𝐀) = 𝐗 𝟏𝟎𝟎
𝟏𝟓𝟑𝐦𝐥
𝟔𝟓𝟎𝐦𝐠
𝐁𝐢𝐨𝐚𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 (𝐁𝐀) = 𝐗 𝟏𝟎𝟎 = 𝟔𝟔. 𝟒%
𝟏𝟓𝟑𝐦𝐥
𝐀𝐔𝐂𝐨𝐫𝐚𝐥 𝟐𝟓
For oral = = 𝐱 𝟏𝟎𝟎 = 𝟔𝟕𝟑. 𝟖%
𝐀𝐔𝐂𝐈𝐕 𝟑
Calculation:
Pharmacokinetics Analysis: Non-compartmental including Vd, Cl, Cmax., Tmax, AUC etc.
AUC = ∫ 𝐂(𝐭). 𝐝𝐭
AUC is area under the curve, C is plasma conc. f drug at time t, dt is infinitely small
incensement of time.
Peak conc. of PCM in blood (mg/mL) with the dose of PCM (mg):
21
Results:
The bioavailability of PCM tablet in animal mice is calculated 66.4% which accesses the
effectiveness of PCM tablet in treating pain & fever in mice. The bioavailability of oral
administration calculated 65-66.66% and after the administration will be calculated 95-
100%
Reference:
➢ Simmaonds, E.A., et all, JR (2013), pharmacokinetics of PCM in mice for IV & oral
administration, British journal of pharmacology, 6 (s3), page. No. 321-336.
➢ Agarwal, V. et all (2006), pharmacokinetics of PCM, “an review Journal of clinical
pharmacy & therapeutics”, 31 (2), page no. 99-113.
22
Experiment No: 06
CLINICAL DATA DEVELOPMENT MANUAL
AIM: To develop a Clinical Data Development Manual
INTRODUCTION:
The purpose of this document is to provide a Manual of Operating Procedures (MOP) template
for principal investigators (PIs) of multisite clinical trials. The role of the MOP is to facilitate
consistency in protocol implementation and data collection across participants and study sites.
Use of the MOP increases the likelihood that the results of the study will be scientifically
credible and provides reassurance that participant safety and scientific integrity are closely
monitored. Investigators of single-site studies are encouraged to consider the template’s
contents. However, a MOP is not mandatory for these studies.
Definition:
A MOP is a handbook that details a study’s conduct and operations. It transforms the study
protocol into a guideline that describes a study’s organization, operational data definitions,
recruitment, screening, enrolment, randomization, follow-up procedures, data collection
methods, data flow, case report forms (CRFs), and quality control procedures. The MOP is
intended to serve as a study “cookbook” that facilitates adherence to study procedures. The
MOP is developed before the study can commence.
During a study's planning phase, the PI and study staff drafts the protocol. The protocol must
be approved by the IRBs of all Institutions participating in the study and by the Data and Safety
Monitoring Board (DSMB). Prior to developing the MOP, the final protocol, CRFs, informed
consent documents, and administrative forms (e.g., screening and enrolment log, protocol
deviation log, etc.) should be finalized. Additionally, if the study is to be submitted to the Food
and Drug Administration (FDA) under an Investigational New Drug Application (IND), an
Investigator's Brochure (for investigational products) or Package Insert (for marketed drugs)
must be included. The timeline for development of study materials must be planned for and
typically takes approximately 6 months.
23
Procedure:
The MOP is a dynamic document that will be updated throughout the conduct of a study to
reflect any protocol or consent amendments as well as the refinement of the CRFs and study
procedures. The MOP should be maintained in a format that allows it to be easily updated, and
is typically filed in a three-hole binder. For ease of organization, it is recommended that the
MOP be subdivided into various sections separated by dividers or sheets of colour paper
between each section. Further, each page of the MOP should contain the version number and
date. As pages are revised, an updated version number and associated date will replace the
original page(s) in the MOP. All previous versions should be archived.
Content:
The MOP details the study procedures and describes the study-specific documents and must be
adapted to each study’s specific needs. It often includes the following sections:
24
• Quality Control Procedures
• Study Completion and Closeout Procedures
• Policies
• MOP Maintenance
The MOP should include all of the relevant sections from this list that apply to the specific
study. If a section does not apply (e.g., randomization for a study with no randomization), it is
not included in the MOP. Additionally, if the study involves a drug intervention, either the
Package Insert for an approved drug or the Investigator’s Brochure for an investigational
product must be included as an appendix.
25
Experiment No: 07
Requirements:
PRINCIPLE:
Cold cream made with borax is more superior to those without it. Since the emulsion is whiter,
smoother and more stable. Borax in excess is required for neutralization but this makes cream
more alkaline without contributing to appearance and stability, while too little borax does not
lead to desired smoothness.
Boil oil phase and aqueous phase should be mixed at equal temperature i.e. 700C to ensure
using mixing of two phases. Perfume should be added when mixture has attained a temperature
of 40-450C.
26
Ingredients Table (Formula):
Dissolve borax in water and heat the aqueous solution to 700C. Melt together beeswax,
mineral oil, and paraffin wax, and heat the oil phase with constant stirring. Continue stirring
until 450C and add the perfume at about 400C and stir till room temperature is attained.
• Washability: The cream was applied on the hand and observed under the running.
• pH: The pH meter was calibrated with the help of standard buffer solution. Weigh 0.5
gm of cream dissolved it in 50.0ml of distilled water and its p H was measured with
the help of digital pH meter.
• Viscosity: Viscosity of the cream was determined with the help of Brookfield
viscometer at 20 rpm with the spindle no LV-4(64)
• Spread ability test: The cream sample was applied between the two glass slides and
was compressed betweenthe two-glass slide to uniform thickness by placing 100 gm
of weight for 5 minutes then weight was added to the weighing pan. The time in which
the upper glass slide moved over the lower slide was taken as a measure of spread
ability.
Spread ability=m *l/t
Where, M =weight tight to upper slide; L =length moved on the glass slide; T= Time
taken
27
• Irritancy test: Mark an area (1sq.cm) on the left-hand dorsal surface. The cream was
applied to the specified area and time was noted. Irritancy, erythema, edema, was
checked if any for regular intervals up to 24 hrs. and reported.
• Saponification value: Take 2 gm of the substance and reflux it with the 25 ml of 0.5 N
alcoholic KOH for 30 minutes. Then add 0.1 ml of phenolphthalein as a indicator and titrate it
with the 0.5 N HCL.
Acid value=n*5.61/w
• Dye test: The scarlet red dye is mixed with the cream. Place a drop of the cream on a
microscopic slide then covers it with a cover slip, and examines it under a microscope.
If the disperse globules appear red the ground colorless. The cream is o/w type. The
reverse condition occurs in w/o type cream i.e. the disperse globules appearcolorless.
• Homogeneity: Homogeneity was tested via the visual appearance and test.
Observation:
28
• pH of the cream: The pH of the cream was found to be in range of ………….
• Viscosity: Viscosity of formulated cream was determined by brook field viscometer
at 20 rpm using spindleno. LV-4(64). The viscosity of cream was in the range of ……
• Spread ability test: The spread ability test showed that the formulated cream has good
spreadable property.
Formula Average spreadbility
FI
• Irritancy test: The formulated cream shows no redness, edema, irritation and
inflammation during studies. The formulated cream is safe to use.
Irritancy test Result
Irritation
Edema
Redness
Swelling
Label:
COLD CREAM
20 gm
Composition:
29
Experiment No: 08
Requirements:
PRINCIPLE:
Vanishing cream is essentially an o/w emulsion which when applied on the skin gives a non-
greasy appearance. The emulsifying agent being potassium or other stearate formed by
action of caustic acid. A humectant such as glycerin is also present. The pH vanishing cream
though variable is usually nearer to neutral.
The cream spreads easily on the skin surface giving a thin semi matt film which seemsto
disappear/vanish after sometimes, hence the name vanishing cream. They are also used to
counter act shine and to protect the skin from dust and wind. A conventional vanishing cream
contains generally 4ingredients viz. Stearic acid, alkali, humectants and water. Additional
ingredients such as perfume, preservative etc. are also added in the preparation. Stearic acid
isthe principal film forming agent in the preparation, which imparts characteristics bloom and
matteffect when the cream is applied on the skin. If The preparation contains too many Oils,
fats, and waxes, the film will not vanish as effectively. Glycerin acts as humectant and also
influences the product in container by reducing drying out of the cream and surface crest
formation as well as providing pearly appearance
The choice and proportion of the alkali used in vanishing cream has much todo with the
ultimate consistency texture and appearance of the cream. Various alkalis used include
potassium hydroxide, ammonia, borax, potassium carbonate and triethanolamine. Of these
potassium Hydroxide is used generally because it makesthe cream of fine texture and excellent
consistency without excessive harshness. The carbonates are not favored as they liberate
carbon. Ammonia is effective but objectionable to turn yellow with age. Borax is used in
combination with JOH/TEA because it produces a very white emulsion. The crystal luster
which gives pearly is due to formation of potassium Stearate.
30
Ingredients Table (Formula):
Quantity taken for 20
Sl. No Ingredients Quantity given (%)
gm
1 Stearic acid 15
2 Potassium hydroxide 0.7
3 Glycerin 8
4 Water 76.3
5 Perfume q.s
Procedure:
A. Formulation of vanishing cream
Dissolve potassium hydroxide in water and then add glycerine. Heat this aqueous mixture to
about 700C. Take stearic acid in china dish and heat to this oily mixture to about 700C in a
water bath. Add the aqueous phase to the oily phase with constant stirring. At 40°C and
perfume and cool till room temperature is attained.
• Washability: The cream was applied on the hand and observed under the running.
• pH: The pH meter was calibrated with the help of standard buffer solution. Weigh 0.5
gm of cream dissolved it in 50.0ml of distilled water and its p H was measured with
the help of digital pH meter.
• Viscosity: Viscosity of the cream was determined with the help of Brookfield
viscometer at 20 rpm with the spindle no LV-4(64)
• Spread ability test: The cream sample was applied between the two glass slides and
was compressed betweenthe two-glass slide to uniform thickness by placing 100 gm
of weight for 5 minutes then weight was added to the weighing pan. The time in which
the upper glass slide moved over the lower slide was taken as a measure of spread
ability.
Spread ability=m *l/t
Where, M =weight tight to upper slide; L =length moved on the glass slide; T= Time
• Irritancy test: Mark an area (1sq.cm) on the left-hand dorsal surface. The cream was
applied to the specified area and time was noted. Irritancy, erythema, edema, was
checked if any for regular intervals up to 24 hrs. and reported.
31
• Saponification value: Take 2 gm of the substance and reflux it with the 25 ml of 0.5 N
alcoholic KOH for 30 minutes. Then add 0.1 ml of phenolphthalein as a indicator and titrate it
with the 0.5 N HCL.
Acid value=n*5.61/w
• Dye test: The scarlet red dye is mixed with the cream. Place a drop of the cream on a
microscopic slide then covers it with a cover slip, and examines it under a microscope.
If the disperse globules appear red the ground colorless. The cream is o/w type. The
reverse condition occurs in w/o type cream i.e. the disperse globules appearcolorless.
• Homogeneity: Homogeneity was tested via the visual appearance and test.
Observation:
32
• Spread ability test: The spread ability test showed that the formulated cream has good
spreadable property.
Formula Average spreadbility
FI
• Irritancy test: The formulated cream shows no redness, edema, irritation and
inflammation during studies. The formulated cream is safe to use.
Irritancy test Result
Irritation
Edema
Redness
Swelling
Label:
VANISHING CREAM
20gm
Composition: BATCH NO.:
Stearic acid MFG. DATE:
Potassium hydroxide, MFG. LIC NO.:
Glycerin, Perfume, EXPIRY DATE:
Purified water
Category: Cosmetics
33
Experiment No: 09
Requirements:
PRINCIPLE:
1. Abrasive: abrasives are used to clean the surface of teeth. At the same time, it
shouldhave no harmful effect on the enamel. It should be non-toxic and non-irritant.
Eg: calcium carbonate, Di and tri calcium phosphate.
2. Surfactant: they are also referred as foaming agents. They bring about wetting
anddispersion of powdered material with lowering of interfacial tension.
Eg: 1) Sodium lauryl sulphate (S.L.S)
Eg: Glycerin is used as humectants. It is sweet, non- toxic and solvent action. Other
examples are sorbitol and propylene glycols are used as humectants.
4. Binding / Gelling agent: Gelling agents are used to make the tooth paste high
solidsuspension stable. It modifies dispensability, and consistency.
Eg: Natural – Irish moss and tragacanth.
Synthetic – cellulose, sodium derivatives, sodium CMC, Hydroxy ethyl cellulose and
methyl cellulose.
5. Flavours: To get fresh, clean sensation.
E.g. spearmint oil, peppermint oil.
34
Other ingredients:
1) Corrosion inhibitors. e.g. sodium silicate.
2) Colour and bleachers (to remove stain) E.g. sodium per borate, magnesium peroxide,
a small amount of sodium fluoride can be incorporated (1000 parts / million parts).
A. Formulation of Toothpaste
• Hydration of gelling agent by adding carboxyl methyl cellulose, glycerine and part
of water with continuous stirring.
• Add the fine powders to the gelling agent with constant stirring.
• Mix to a paste.
B. Evaluation of Toothpaste
• Drying Tendency: All the formulated batches were evaluated for their drying tendency
at room temperature for a week.
• Organoleptic Characters: Formulated batches were also evaluated for their
organoleptic characters.
35
• Determination of pH: In 100 ml cleaned beaker, accurately weighed 5 gm of sample
was transferred. To this freshly boiled and cooled water was added and stirred well to
get a uniform suspension. The pH was determined within 5 min by using a pH meter
(M/s. Systronics Ltd. Ahmedabad). Results were tabulated in Table 5.
• Determination of Foaming Power: In 100 ml glass beaker near about 5 gm of sample
was taken. To this 40 ml, water was added, and the beaker was allowed to stand for 30
min by covering with a watch glass for dispersion of toothpaste in water. Then the
content was stirred with glass rod and slurry was transferred to a 250 ml graduated
measuring cylinder. Precaution was taken at the time of transfer that no loss was
produced. The reaming residue in the beaker was transferred with 5 to 6 ml of another
portion of water. The volume make up to 50 ml by adding sufficient quantity of water
and the temperature of the content is maintained near about 30 ºC, meanwhile stirring
was continued to ensure uniform suspension. When the temperature of the content was
reached to 30 ºC the stirring was stopped and 12 complete shakes were given and
allowed to stand for 5 min. The foaming power was determined by measuring volume
of foam with water (V1) and water only (V2) was noted for all samples.
Foaming power = V1 – V2
Observation:
• Drying Tendency, Organoleptic Characters & Determination of Grittiness:
Evaluation parameters
Batch
Dryness test Colour Appearance Extrudability Texture After taste
36
Label:
TOOTHPASTE
20gm
Composition: BATCH NO.: MFG. DATE:
37
Experiment No: 10
Requirements:
PRINCIPLE:
Shampoos are one which is designed to provide sufficient cleaning powder to get adequate
foam, to remove the oil from the hair and the scalp without reducing the natural oiliness, so
that the hair is left with a natural gloss, soft and in manageable condition.
Properties / characteristics of shampoo
1. It should remove all the build-up from the hair as well as the scalp.
38
Ingredients Table (Formula):
A. Formulation of Shampoo
1. Dissolve potassium hydroxide in small quantity of water.
2. Transfer measured amount of coconut oil and Castor oil into a dry beaker and keep it
in hot waterbath.
3. Pour alkaline solution in a stream to the oil phase with continuous stirring.
4. Continuous stirring to complete the saponification process until the soap is formed.
5. After saponification, add glycerine, Borax and stir for 10 min. NOTE: add alcohol into
the beaker if required.
6. Transfer into a container, label and submit.
B. Evaluation of Shampoo
• Physical appearance/visual inspection
The formulations were evaluated in terms of their clarity, color, odor and texture.
• Determination of pH
pH of your 10% shampoo solution. Dip one strip of pH paper in the solution and
compare the color of the strip to key. pH meter can also be used after calibration.
Most shampoos are neutral or slightly acidic. Acidic solutions cause the cuticle (outer
layer) of the hair to shrink and lay flatter on the shaft of the hair. Basic solutions cause
the cuticle to swell and open up. Acidic solutions make the hair seem smoother. Basic
solutions make hair seem frizzier.
39
Neutral pH = 7 Acidic pH < 7 Basic pH >7
• Dirt dispersion
Two drops of shampoo were added in a large test tube contain 10 ml of distilled water.
1 drop of India ink was added; the test tube was stoppered and shakes it ten times. The
amount of ink in the foam was estimated as None, Light, Moderate, or Heavy.
Shampoos that cause the ink to concentrate in the foam are considered poor quality.
The dirt should vstay in the water portion. Dirt that stays in the foam will be difficult to
rinse away. It will redeposit on the hair.
A clean dry evaporating dish was weighed and added 4 grams of shampoo to the
evaporating dish. The dish and shampoo was weighed. The exact weight of the shampoo
was calculated only and put the evaporating dish with shampoo was placed on the hot
plate until the liquid portion was evaporated. The weight of the shampoo only (solids)
after drying was calculated. If a shampoo has too many solids it will be hard to work
into the hair or too hard to wash out. If it doesn’t have enough it will be too watery and
wash away quickly. A good shampoo will be between 20% – 30% solids.
Measurements were carried out with a 10% shampoo dilution in distilled water at room
temperature. Thoroughly clean the stalagmometer using chronic acid and purified
water.
Because surface tension is highly affected with grease or other lubricants. The data
calculated by following equation given bellow:
R2 = (w3-w2) n1 R2 (W2-w2)n2
40
• Cleaning action
5 grams of wool yarn were placed in grease; after that it was placed in 200 ml. of water
containing 1 gram of shampoo in a flask. Temperature of water was maintained at 350C.
The flask was shaked for 4 minutes at the rate of 50 times a minute.
The solution was removed and sample was taken out, dried and weighed. The amount
of grease removed was calculated by using the following equation:
DP = 100 (1-T/C)
• Wetting time
The canvas was cut into 1-inch diameter discs having an average weight of 0.44 g. The
disc was floated on the surface of shampoo solution of 1% w/v and the stopwatch
started. The time required for the disc to begin to sink was measured acutely and noted
as the wetting time.
Cylinder shake method was most widely used for determining foaming ability. 50 ml
of the 1% shampoo solution was put into a 250 ml graduated cylinder and covered the
cylinder with hand and shaken for 10 times. The total volumes of the foam contents
after 1-minute shaking were recorded. The foam volume was calculated only.
Immediately after shaking the volume of foam at 1 minute intervals for 4 minutes were
recorded.
Observation:
41
• Evaluation of Formulation for Surface tension and % solid contents
42
Label:
Report: 20 ml of clear liquid shampoo was prepared, evaluated, labelled and submitted.
43
Experiment No: 11
AIM: To address Dry Skin, Acne, Blemish, Wrinkles, Bleeding Gums and Dandruff
Requirements:
PRINCIPLE:
A. Dry Skin
Xeroderma, also known as dry skin, xerosis cutis, or asteatosis, is a prevalent condition
resulting from inadequate hydrolipids in the skin. This deficiency can manifest as
roughness, tightness, flaking, and scaling of the skin, resulting from various factors
such as age, underlying medical conditions, medications, or environmental changes.
This activity provides learners with insights into the evaluation and holistic
management of xeroderma, including strategies to alleviate pruritus, minimize the risk
of skin infections, and ultimately improve patient outcomes.
B. Acne
Acne is an inflammatory disorder of the skin, which has sebaceous (oil) glands that
connects to the hair follicle, which contains a fine hair. In healthy skin, the sebaceous
glands make sebum that empties onto the skin surface through the pore, which is an
opening in the follicle. Keratinocytes, a type of skin cell, line the follicle. Normally
as the body sheds skin cells, the keratinocytes rise to the surface of the skin.
Acne causes several types of lesions, or pimples. Doctors refer to enlarged or plugged
hair follicles as comedones. Types of acne include: Whiteheads, Blackheads, Papules,
Pustules or pimples, Nodules, Severe nodular acne
44
C. Wrinkles
Wrinkles are creases in the skin. The medical term for wrinkles is rhytids. Most
wrinkles come from aging. Aging of the skin, hair and nails is a natural process.
Frequent or prolonged exposure to sunlight results in early skin wrinkles and dark areas.
It also increases the chances of getting skin cancer. Exposure to cigarette smoke can
also make the skin wrinkle sooner. Common causes of wrinkles include: Genetic factors
(family history), Normal aging changes in the skin, Smoking, Sun exposure
D. Blemish
A blemish is the term for any mark on the skin. There are many different types of
blemish, including acne, papules, and changes in pigmentation. They can appear
anywhere on the body, including the face. Most blemishes are harmless, but some
people may wish to treat them for cosmetic reasons.
E. Dandruff
Dandruff is a scalp condition that causes flakes of skin to appear. There may also be
itching. Most people experience dandruff at some point, but it is more common from
the teenage years up to midlife. There are various possible causes, including seborrheic
dermatitis, allergic reactions, psoriasis, and eczema.
Procedure:
• Weight the quantity of steric acid, lanolin & mineral oil. Place it in 150 ml
beaker
• Heat the mixture to a temp 80⁰ to 90⁰ C. Add the triethanolamine slowly to the
melted mixture with constant stirring
45
Ingredients Table (Formula):
46
Ingredients Table (Formula):
Sl. No Ingredients Quantity taken
1 Bees wax 10 g
2 Emulsifying Wax 10 g
3 Almond oil 40 ml
4 Lanolin 20 g
5 Coconut oil 20 g
6 Orange flower oil 30 ml
7 Tincture benzoin 0.5 ml
8 Orange oil 0.5 ml
D. Procedure for preparation of cream for Blemish
• The emulsifying wax & other oil soluble components were dissolved in oil
phase (Part A) & heated upto 80⁰C
• Extract & water soluble components were dissolved in Part B & heated upto
80⁰C
• After heating, the aqueous phase was added in portion to the oil phase with
constant stirring until cream is formed.
Ingredients Table (Formula):
Sl. No Ingredients Quantity taken
1 Extract 2g
2 Petroleum Jelly 4.3 g
3 Hard paraffin 2g
4 Cetyl alcohol 0.5 ml
5 Glyceryl monostearate 0.5 g
6 Methyl paraben 0.4 g
7 Propyl paraben 0.3 g
8 Fragrance Q. S.
9 Activated charcoal 0.01 g
E. Procedure for preparation of Anti-Dandruff Shampoo
• The anti-dandruff shampoo was formulated using simple mixing process.
• Formulation were made by using two antidandruff agents such as Sulphur &
benzoic acid.
47
Ingredients Table (Formula):
Report: Cosmeceuticals for Dry Skin, Acne, Blemish, Wrinkles, Bleeding Gums and Dandruff
were prepared and addressed.
48
Vision and Mission of the Institution
Vision
The East Point College of Pharmacy aspires to be a globally acclaimed institution,
recognized for excellence in pharmaceutical education, research and nurturing
students for holistic development.
Mission
M1 Create pharmacy graduates through quality education